Mytos and Pluristyx Enter Strategic Collaboration to Automate Manufacturing of GMP Lines for Regenerative Medicines
December 11, 2025
London / Seattle – Mytos, a leader in automated regenerative medicine manufacturing and Pluristyx, a leading provider of GMP induced pluripotent stem cell (iPSC) based solutions, today announced a strategic collaboration to automate the manufacture of Pluristyx’s clinical-grade cell lines for use in regenerative medicine manufacturing. Mytos will leverage its automated manufacturing platform (iDEM™) and CDMO infrastructure, while Pluristyx will contribute its clinical-grade iPSC platform, engineered cell lines, cryomedia and technology services to bring an integrated end-to-end solution to the marketplace.
This collaboration addresses a critical bottleneck in the regenerative medicine and cell therapy industry: developing scalable, cost-efficient, GMP-ready manufacturing capacity that can rapidly and reproducibly support translation from research into the clinic and beyond. With Mytos’ iDEM™ automation platform and Pluristyx’s suite of engineered iPSC lines (including tools such as iACT™ immune-cloaking and FailSafe® safety-switch technologies), the partnership aims to provide cell therapy developers with a streamlined, high-quality manufacturing pathway.
Mytos CEO Dr. Ali Afshar said, “Bringing regenerative medicines to millions of patients will require manufacturing of the highest quality cells at scale. Our collaboration with Pluristyx enables a powerful combination of automation and engineered cell platforms, taking a meaningful step toward accessible, high-quality manufacturing of regenerative medicines.”
Pluristyx CEO Dr. Benjamin Fryer said, “We are excited to partner with Mytos and combine our engineered iPSC platform with their automated manufacturing capabilities. This collaboration brings us closer to the vision of offering developers a complete, GMP-ready solution from high-quality starting material to process automation to unlock scale, so they can focus on therapeutic innovation and patient impact.”
About Mytos
Mytos is a leader in automated cell manufacture. The company’s platform enables life sciences companies to grow human cells with unparalleled precision and efficiency. Mytos has assembled a world-class team of engineers and scientists to develop an automated platform to accelerate the development of life-saving therapies. The company is based in London, UK. For more information, visit www.mytos.bio.
About Pluristyx
Pluristyx is the leading provider of advanced iPSC-based solutions for the cell and gene therapy industry, delivering a comprehensive platform designed to accelerate therapeutic development with unmatched speed, safety, and scalability. Leveraging proprietary mRNA bulk reprogramming and a polyclonal iPSC approach, Pluristyx produces genetically younger, more stable, and highly expandable cells. The company’s portfolio spans off-the-shelf, clinical-grade iPSC lines, custom gene editing and engineering, and innovative safety and immune-evasion technologies, including the FailSafe® safety switch, iACT™ immune cloaking system, and HLA-null capabilities. Beyond cell sourcing, Pluristyx supports the entire development continuum, from concept to organoid-based disease modeling, high-throughput drug screening, and GMP-scale manufacturing, empowering therapeutic developers to streamline workflows, reduce risk, and accelerate the path to clinic.
Media Contact:
Ignacio Willats
Chief Commercial Officer & Co-Founder
ignacio@mytos.bio